In patients with symptomatic, severe mitral regurgitation (MR) undergoing transcatheter mitral valve replacement (TMVR), the AltaValve system shows sustained clinical benefits, reduction of MR and potential treatment strategies for several mitral valve (MV) anatomies, according to the updated results from the AltaValve early feasibility study (EFS).